Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelo Castello

Showing results (11-20 of 80) with videos related to

Pageof 8
Sort By:
Seminars in Nuclear Medicine|August 14, 2022
FDG PET/CT for Staging and Restaging Malignant MesotheliomaEgesta Lopci, Angelo Castello, Luigi Mansi
Current Radiopharmaceuticals|December 31, 2019
18F-FDG PET/CT in Restaging and Evaluation of Response to Therapy in Lung Cancer: State of the ArtAngelo Castello, Sabrina Rossi, Egesta Lopci
American Journal of Nuclear Medicine and Molecular Imaging|March 14, 2018
Adenoid cystic carcinoma: focus on heavy ion therapy and molecular imagingAngelo Castello, Laura Olivari, Egesta Lopci
Cancer Biotherapy & Radiopharmaceuticals|February 2, 2023
Novelties from the Joint EANM/SNMMI/ANZSNM Guidelines on ImmunotherapyEgesta Lopci, Angelo Castello, Luca Filippi
Immunotherapy|July 17, 2018
Immunotherapy in non-small-cell lung cancer: potential predictors of response and new strategies to assess activitySabrina Rossi, Angelo Castello, Luca Toschi, et al.
Journal of Clinical Medicine|April 3, 2021
Impact of Antibiotic Therapy and Metabolic Parameters in Non-Small Cell Lung Cancer Patients Receiving Checkpoint InhibitorsAngelo Castello, Sabrina Rossi, Luca Toschi, et al.
Frontiers in Oncology|August 28, 2020
Comparison of Metabolic and Morphological Response Criteria for Early Prediction of Response and Survival in NSCLC Patients Treated With Anti-PD-1/PD-L1Angelo Castello, Sabrina Rossi, Luca Toschi, et al.
Molecular Imaging and Biology|November 28, 2018
Prognostic Impact of Intratumoral Heterogeneity Based on Fractal Geometry Analysis in Operated NSCLC PatientsAngelo Castello, Carlo Russo, Fabio Grizzi, et al.
Cancers|May 31, 2020
Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors and Its Correlation with Metabolic ParametersAngelo Castello, Sabrina Rossi, Luca Toschi, et al.
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|July 3, 2025
Navigating response criteria in mCRPC: role of PSMA PET/CT and new insightsAngelo Castello, Matteo Caracciolo, Mirco Bartolomei, et al.
Pageof 8

Showing results (11-20 of 80) with videos related to

Sort By:
Pageof 8
Seminars in Nuclear Medicine|August 14, 2022
FDG PET/CT for Staging and Restaging Malignant MesotheliomaEgesta Lopci, Angelo Castello, Luigi Mansi
Current Radiopharmaceuticals|December 31, 2019
18F-FDG PET/CT in Restaging and Evaluation of Response to Therapy in Lung Cancer: State of the ArtAngelo Castello, Sabrina Rossi, Egesta Lopci
American Journal of Nuclear Medicine and Molecular Imaging|March 14, 2018
Adenoid cystic carcinoma: focus on heavy ion therapy and molecular imagingAngelo Castello, Laura Olivari, Egesta Lopci
Cancer Biotherapy & Radiopharmaceuticals|February 2, 2023
Novelties from the Joint EANM/SNMMI/ANZSNM Guidelines on ImmunotherapyEgesta Lopci, Angelo Castello, Luca Filippi
Immunotherapy|July 17, 2018
Immunotherapy in non-small-cell lung cancer: potential predictors of response and new strategies to assess activitySabrina Rossi, Angelo Castello, Luca Toschi, et al.
Journal of Clinical Medicine|April 3, 2021
Impact of Antibiotic Therapy and Metabolic Parameters in Non-Small Cell Lung Cancer Patients Receiving Checkpoint InhibitorsAngelo Castello, Sabrina Rossi, Luca Toschi, et al.
Frontiers in Oncology|August 28, 2020
Comparison of Metabolic and Morphological Response Criteria for Early Prediction of Response and Survival in NSCLC Patients Treated With Anti-PD-1/PD-L1Angelo Castello, Sabrina Rossi, Luca Toschi, et al.
Molecular Imaging and Biology|November 28, 2018
Prognostic Impact of Intratumoral Heterogeneity Based on Fractal Geometry Analysis in Operated NSCLC PatientsAngelo Castello, Carlo Russo, Fabio Grizzi, et al.
Cancers|May 31, 2020
Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors and Its Correlation with Metabolic ParametersAngelo Castello, Sabrina Rossi, Luca Toschi, et al.
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|July 3, 2025
Navigating response criteria in mCRPC: role of PSMA PET/CT and new insightsAngelo Castello, Matteo Caracciolo, Mirco Bartolomei, et al.
Pageof 8